The significant downregulation of MT1G in prostate cancer tissues, associated with poor prognosis, and its role in regulating the tumor microenvironment and immune response highlight its utility not only as a prognostic marker but also as a potential therapeutic target. This evidence concerns the gene MT1G and prostate cancer.